New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
08:43 EDTPPHMPeregrine updates top-line data from Phase 2 clinical trial of Bavituximab
Peregrine Pharmaceuticals reported data from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer, or NSCLC. Data from the trial has been updated based on completion of an earlier review of discrepancies in the trial and the most current survival data from the trial. Updated results from this Phase II trial indicate a meaningful improvement in median overall survival of 11.7 months in the 3mg/kg bavituximab + docetaxel arm compared to 7.3 months in the control arm. Persistent separation in the survival curves was observed with response rates and progression free survival also favoring the 3mg/kg bavituximab + docetaxel arm in this difficult to treat second-line NSCLC. The results also demonstrated that bavituximab was well-tolerated with no significant differences in adverse events between the trial arms. Peregrine plans to report additional data from the trial, including updated subgroup analysis and safety data, at an upcoming scientific meeting.
News For PPHM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 17, 2014
14:50 EDTPPHMBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
09:46 EDTPPHMSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 15, 2014
12:36 EDTPPHMOn The Fly: Midday Wrap
Subscribe for More Information
10:49 EDTPPHMEbola linked names rise again amid broader market sell-off
Subscribe for More Information
10:49 EDTPPHMHigh option volume stocks
High option volume stocks: SNV FCG TXT MDSO PPHM NTRS CCL RGP LLTC SOCL
09:20 EDTPPHMOn The Fly: Pre-market Movers
Subscribe for More Information
08:38 EDTPPHMPeregrine up 21% after saying will examine drug as potential Ebola treatment
08:15 EDTPPHMPeregrine says data support Phosphatidylserine as potential target in Ebola
Peregrine Pharmaceuticals announced the publication of a peer-reviewed manuscript, to appear in the Vaccines and Therapies for Biodefense Agents special edition of the peer-reviewed Journal of Immunology Research in a manuscript titled: "Effective Binding of a Phosphatidylserine-Targeting Antibody to Ebola Virus Infected Cells and Purified Virions," related to preclinical research demonstrating that the company's lead drug candidate bavituximab, a phosphatidylserine-targeting antibody, exhibits specific and strong binding to Ebola virions and Ebola virus-infected cells in vitro. Cyril Empig, Ph.D., associate research director at Peregrine Pharmaceuticals, said, "Our goal with this work was to continue exploring the potential of bavituximab in the antiviral arena and in this case, specifically in biodefense applications. With the increased focus on Ebola, there is an opportunity to take advantage of the specificity of bavituximab for Ebola virus and develop therapeutics or treatment regimens that could neutralize the virus. In addition, recently reported genomic sequence variations in EBOV suggest that drugs targeting specific viral non-variant proteins or protein sequences are at risk of failure as a result of virus escape mutations...Given these data, we are developing a plan to explore potential applications of bavituximab and PS-targeting antibodies in the treatment of Ebola."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use